Jan-Stefan van der Walt
Overview
Explore the profile of Jan-Stefan van der Walt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
300
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takahashi M, Tokunaga E, Mori J, Tanizawa Y, van der Walt J, Kawaguchi T, et al.
Breast Cancer
. 2021 Oct;
29(1):174-184.
PMID: 34661821
Background: This was a Japanese subpopulation analysis of MONARCH 3, a randomized, double-blind, placebo-controlled phase 3 study of abemaciclib plus nonsteroidal aromatase inhibitors (NSAIs) for initial therapy for advanced breast...
2.
Inoue K, Masuda N, Iwata H, Takahashi M, Ito Y, Miyoshi Y, et al.
Breast Cancer
. 2021 Apr;
28(5):1038-1050.
PMID: 33797023
Background: This was a Japanese subpopulation analysis of MONARCH 2, a double-blind, randomized, placebo-controlled, phase 3 study of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor...
3.
Chigutsa E, Kambhampati S, Karen Sykes A, Posada M, van der Walt J, Turner P
CPT Pharmacometrics Syst Pharmacol
. 2020 Jul;
9(9):523-533.
PMID: 32683787
Abemaciclib is an oral anticancer drug that inhibits cyclin dependent kinases 4 and 6 and is metabolized by cytochrome P450 3A in the intestines and liver to active metabolites. The...
4.
Kierzek A, Hickling T, Figueroa I, Kalvass J, Nijsen M, Mohan K, et al.
CPT Pharmacometrics Syst Pharmacol
. 2019 Sep;
8(11):773-776.
PMID: 31529677
No abstract available.
5.
Earp J, Mehrotra N, Peters K, Fiorentino R, Griebel D, Lee S, et al.
J Pediatr Gastroenterol Nutr
. 2016 Nov;
65(3):272-277.
PMID: 27875488
Objectives: Food and Drug Administration approval of proton-pump inhibitors for infantile gastroesophageal reflux disease has been limited by intrapatient variability in the clinical assessment of gastroesophageal reflux disease. For children...
6.
Gibbons J, de Vries M, Krauwinkel W, Ohtsu Y, Noukens J, van der Walt J, et al.
Clin Pharmacokinet
. 2015 May;
54(10):1057-69.
PMID: 25929560
Background And Objectives: Two phase I drug interaction studies were performed with oral enzalutamide, which is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Methods: A parallel-treatment design...
7.
Gibbons J, Ouatas T, Krauwinkel W, Ohtsu Y, van der Walt J, Beddo V, et al.
Clin Pharmacokinet
. 2015 Apr;
54(10):1043-55.
PMID: 25917876
Background And Objectives: Oral enzalutamide (160 mg once daily) is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This article describes the pharmacokinetics of enzalutamide and its active...
8.
Choy S, Henin E, van der Walt J, Kjellsson M, Karlsson M
J Pharmacokinet Pharmacodyn
. 2012 Nov;
40(1):1-10.
PMID: 23179858
The integrated glucose-insulin (IGI) model is a previously developed semi-mechanistic model that incorporates control mechanisms for the regulation of glucose production, insulin secretion, and glucose uptake. It has been shown...
9.
Zhang C, Denti P, van der Walt J, Ren Y, Smith P, Karlsson M, et al.
Ther Drug Monit
. 2012 Jun;
34(4):481-4.
PMID: 22722777
Background: Interpretation of antiretroviral drug concentration measurements could be aided by information about adherence to recent doses. We developed a population pharmacokinetic model of lamivudine in young children to propose...
10.
Svensson E, van der Walt J, Barnes K, Cohen K, Kredo T, Huitema A, et al.
Br J Clin Pharmacol
. 2012 Feb;
74(3):465-76.
PMID: 22300396
Aims: To propose a modelling strategy to efficiently integrate data from different sources in one simultaneous analysis, using nevirapine population pharmacokinetic data as an example. Methods: Data from three studies...